Role of gabapentin in reducing the need for high-risk medications in patients with stable severe neurological impairment.

Objective: The study was aimed at assessing the prevalence of pain behaviors in children with severe neurological impairment (SNI), as well as the use of prescribed pain behavior medications, and the effects of gabapentin initiation on behaviors and use.

Methods: A pre-post study was conducted on data from 11 patients with SNI who received gabapentin at a children's hospital in Canada. Symptoms and the use of high-risk pain behavior medications were assessed before and after gabapentin initiation and titration.

Results: Pain was identified as a primary concern in most patients (8/11 [73%]) before gabapentin initiation. Dystonia was the most prevalent pain behavior (6/11 [55%]). Of the 11 patients, eight (73%) were taking benzodiazepines for symptom management, four (36%) were taking opioids, and one was taking a hypnotic sedative. Symptom improvement was observed in 10/11 (91%) patients after gabapentin initiation and titration. The use of benzodiazepine decreased in 6/8 (75%) patients, opioid use decreased in 3/4 patients, and hypnotic sedative use decreased in 1/1 patient. Successful discontinuation occurred for benzodiazepines in 5/8 (62.5%) patients, opioids in 1/4 (25%) patients, and hypnotic sedatives in 1/1 patient.

Conclusions: Prescription medications with substantive risks, including benzodiazepines, opioids, and hypnotic sedatives, were used with high prevalence for pain behaviors in children with SNI. This study revealed an association between gabapentin initiation, and improved symptom burden and decreased use of the three medications.